Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study.

Andreyev HJN, Matthews J, Adams C, Gothard L, Lucy C, Tovey H, Boyle S, Anbalagan S, Musallam A, Yarnold J, Abraham D, Bliss J, Abdi BA, Taylor A, Hauer-Jensen M

Open source

DOI: 10.1016/j.radonc.2022.01.024
Published: 2022 Mar
Container: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.radonc.2022.01.024,
  title = {Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study.},
  author = {Andreyev HJN and Matthews J and Adams C and Gothard L and Lucy C and Tovey H and Boyle S and Anbalagan S and Musallam A and Yarnold J and Abraham D and Bliss J and Abdi BA and Taylor A and Hauer-Jensen M},
  year = {2022},
  journal = {Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
  doi = {10.1016/j.radonc.2022.01.024},
  url = {https://doi.org/10.1016/j.radonc.2022.01.024}
}

RIS

TY  - JOUR
TI  - Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study.
AU  - Andreyev HJN
AU  - Matthews J
AU  - Adams C
AU  - Gothard L
AU  - Lucy C
AU  - Tovey H
AU  - Boyle S
AU  - Anbalagan S
AU  - Musallam A
AU  - Yarnold J
AU  - Abraham D
AU  - Bliss J
AU  - Abdi BA
AU  - Taylor A
AU  - Hauer-Jensen M
PY  - 2022
JO  - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
DO  - 10.1016/j.radonc.2022.01.024
UR  - https://doi.org/10.1016/j.radonc.2022.01.024
ER  -

APA

HJN, A., J, M., C, A., L, G., C, L., H, T., S, B., S, A., A, M., J, Y., D, A., J, B., BA, A., A, T., & M, H. (2022). Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. https://doi.org/10.1016/j.radonc.2022.01.024

Source records

pubmed · retrieved 2026-09-25T12:17:50.946Z